search
Back to results

Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage

Primary Purpose

Intracranial Hemorrhages, Traumatic Brain Injury

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SENSE Device
Sponsored by
Sense Diagnostics, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Intracranial Hemorrhages

Eligibility Criteria

22 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female patients age 22 years and older
  • Diagnostic head CT scan within 24 hours of primary spontaneous ICH (parenchymal ICH without secondary causes, such as arteriovenous malformation, cavernoma, aneurysm, hemorrhagic transformation of ischemic stroke, venous sinus thrombosis) symptom onset or traumatic intracranial bleeding (defined as epidural hemorrhage, subdural hemorrhage and/or traumatic contusions/ intraparenchymal hemorrhage)
  • Signed written informed consent by study subject or, if subject is unable, by subject's next of kin or legal guardian
  • Willingness and ability to comply with schedule for study procedures

Exclusion Criteria:

  • • Female patients who are pregnant or lactating

    • Known history of seizure or clinical seizure prior to initiating SENSE monitoring Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for the SENSE device monitoring or study participation or may confound the outcome of the study
    • Planned placement of an intraventricular catheter after the diagnostic (pre-enrollment) CT
    • In stroke patients, secondary cause of ICH suspected (e.g., arteriovenous malformation, cavernoma, aneurysm, hemorrhagic transformation ischemic stroke, venous sinus thrombosis)
    • Planned withdrawal of care within 24 hours of enrollment
    • Planned surgical evacuation within 24 hours of enrollment
    • Current participation in a medical or surgical interventional clinical trial
    • Planned or current use of continuous EEG monitoring

Sites / Locations

  • GradyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Intracranial Hemorrhage

Traumatic Brain Injury

Arm Description

The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts: A molded plastic headpiece containing the antenna array An intermediate control unit that contains: a. The driving electronics for the array of antennae A processing control unit that contains: A spectrum analyzer The operating software that controls the device function and data acquisition, processing and archiving. The user interface for inputting patient information and displaying the output of the data

The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts: A molded plastic headpiece containing the antenna array An intermediate control unit that contains: a. The driving electronics for the array of antennae A processing control unit that contains: A spectrum analyzer The operating software that controls the device function and data acquisition, processing and archiving. The user interface for inputting patient information and displaying the output of the data

Outcomes

Primary Outcome Measures

Primary Outcome
Detection of ICH is the primary endpoint for this study. To establish the sensitivity (primary) and specificity (key secondary) for ICH detection. The results from the CT (ICH versus no ICH) scan will serve as the gold standard.

Secondary Outcome Measures

Full Information

First Posted
November 19, 2020
Last Updated
September 25, 2023
Sponsor
Sense Diagnostics, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT04642443
Brief Title
Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage
Official Title
A Prospective, Two-Stage, Non-randomized, Multi-center Within Patient Comparison Study to Evaluate the SENSE Device's Ability to Detect Intracranial Hemorrhage
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 23, 2020 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
September 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sense Diagnostics, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a two-stage, pivotal, prospective, non-randomized, multi-center, within patient comparison of the SENSE device and the standard diagnostic test, head CT scan in patients with a diagnosis of primary spontaneous ICH or traumatic intracranial bleeding for the detection and monitoring of intracranial hemorrhages.
Detailed Description
This study is a two-stage, pivotal, prospective, nonrandomized, multi-center, within patient comparison of the SENSE device and the standard diagnostic test, head CT scans. All subjects who meet eligibility criteria should be enrolled. An algorithm has been developed for detecting ICH, which will now be tested in this independent cohort of subjects. CT scans will be grouped into: 1) ICH, or 2) non- ICH. Enrollment will continue until 120 subjects with and 120 without ICH have been enrolled. An interim analysis will occur after ~60 subjects each with and without ICH have been enrolled and the sample size may be increased at the direction of the DMC as warranted. In Stage 1, 150 subjects (with primary spontaneous ICH or traumatic intracranial hemorrhage) were enrolled for the development of a hemorrhage detection algorithm. In Stage 2, the algorithm developed in Stage 1 will be tested in an independent cohort of up to 300 subjects. All subjects who meet eligibility criteria should be enrolled. The gold standard will be the CT results. The algorithm established in Stage 1 will be tested in this independent cohort of subjects. CT scans will be grouped into: 1) ICH or, 2) non-ICH. Enrollment will continue until ~60 subjects each with and without ICH have been enrolled. An interim analysis will occur after ~60 subjects each with and without ICH have been enrolled and the sample size may be increased at the direction of the DMC as warranted. All subjects' CT images will be reviewed by an independent neuroradiology core for classification as ICH or non-ICH, and ICH volume estimation. The treating clinicians and independent neuroradiologist will be blinded to the SENSE device findings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intracranial Hemorrhages, Traumatic Brain Injury

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
450 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intracranial Hemorrhage
Arm Type
Active Comparator
Arm Description
The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts: A molded plastic headpiece containing the antenna array An intermediate control unit that contains: a. The driving electronics for the array of antennae A processing control unit that contains: A spectrum analyzer The operating software that controls the device function and data acquisition, processing and archiving. The user interface for inputting patient information and displaying the output of the data
Arm Title
Traumatic Brain Injury
Arm Type
Active Comparator
Arm Description
The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of three parts: A molded plastic headpiece containing the antenna array An intermediate control unit that contains: a. The driving electronics for the array of antennae A processing control unit that contains: A spectrum analyzer The operating software that controls the device function and data acquisition, processing and archiving. The user interface for inputting patient information and displaying the output of the data
Intervention Type
Device
Intervention Name(s)
SENSE Device
Intervention Description
The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.
Primary Outcome Measure Information:
Title
Primary Outcome
Description
Detection of ICH is the primary endpoint for this study. To establish the sensitivity (primary) and specificity (key secondary) for ICH detection. The results from the CT (ICH versus no ICH) scan will serve as the gold standard.
Time Frame
24-hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patients age 22 years and older CT obtained in the mobile stroke unit, emergency department (ED) or hospital Exclusion Criteria: Female patients who are pregnant or lactating SENSE device cannot be applied within 6 hours of a standard of care CT, Metallic intracranial clip, coil, device (such as ICP monitor), or penetrating metallic shrapnel, Metallic EEG leads in place at the time of planned enrollment, Open skull fracture (closed skull fracture is not an exclusion), Placement of an intraventricular catheter prior to enrollment, Hemorrhagic transformation of ischemic stroke,) as etiology of ICH, Treatment with intravenous thrombolysis or embolectomy prior to enrollment, Clinical uncertainty about whether intracranial hemorrhage is present on the pre-enrollment head CT, and Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for SENSE device monitoring or study participation or may confound the outcome of the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alex Hall, BSN
Phone
404-778-1585
Email
alex.hall@emory.edu
First Name & Middle Initial & Last Name or Official Title & Degree
sara m keegan, MEd
Phone
513-584-0470
Email
sara.stark@uc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathan Ratcliff, MD
Organizational Affiliation
Emory University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Grady
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30303
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathan Ratcliff, MD
First Name & Middle Initial & Last Name & Degree
Jonathan Ratcliff, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage

We'll reach out to this number within 24 hrs